

a-19

A

<b>NON FEE UTILITY Patent Application Transmittal</b> <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>		Attorney Docket Number	STAN201	
		First Named Inventor	Gerald R. Crabtree et al.	
		Title	Methods and Compositions for Modulating Angiogenesis	
		Express Mail Label No.	EL852296815US	
<b>APPLICATION ELEMENTS</b> <small>See MPEP chapter 600 concerning utility patent application contents.</small>		<b>ADDRESS TO:</b> <small>Assistant Commissioner for Patents Box Patent Application Washington, DC 20231</small>		
1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <small>(Submit an original and a duplicate for fee processing)</small>		7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)		
2. <input checked="" type="checkbox"/> Applicant claims small entity status. <small>See 37 CFR 1.27.</small>		8. Nucleotide and/or Amino Acid Sequence Submission <small>(if applicable, all necessary)</small>		
3. <input checked="" type="checkbox"/> Specification <small>(preferred arrangement set forth below)</small> <ul style="list-style-type: none"> <li>- Descriptive title of the invention</li> <li>- Cross Reference to Related Applications</li> <li>- Statement Regarding Fed sponsored R&amp;D</li> <li>- Reference to sequence listing, a table, or a computer program listing appendix</li> <li>- Background of the Invention</li> <li>- Brief Summary of the Invention</li> <li>- Brief Description of the Drawings (if filed)</li> <li>- Detailed Description</li> <li>- Claims(s)</li> <li>- Abstract of the Disclosure</li> </ul>		Total Pages	33	
4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113)		Total Sheets	1	
5. Oath or Declaration		Total Pages		
a. <input type="checkbox"/> Newly executed (original or copy)				
b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d))		i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> <small>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)</small>		
6. <input checked="" type="checkbox"/> Application Data Sheet, See 37 CFR 1.76				
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP)    of prior application No: _____ Prior Application Information: _____ Examiner: _____ Group Art Unit: _____ For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.				
<b>Fee Calculation</b> <b>CLAIMS AS FILED</b>				
For	# Filed	# Allowed	# Extra	Rate
Total Claims	29	20	9	X
Indep. Claims	4	3	1	X
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>				
BASIC FEE				
OTHER FEE (specify purpose) _____				
TOTAL FILING FEE				


**Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)**

19.  Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

***Warning***

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

**20. CORRESPONDENCE ADDRESS**

Name (Print/Type)		Bret E. Field	Registration No.	37,620	
Signature				Date	09-19-2001
Firm Name	Bozicevic, Field & Francis LLP		Address	200 Middlefield Road, Suite 200	
City	Menlo Park	State	California	zip	94025
Telephone - Direct Dial		650-833-7705		Fax	650-327-3231